Phase III inMIND trial: Efficacy and safety of tafasitamab plus lenalidomide and rituximab for R/R FL

The inMIND trial (NCT04680052) is a double-blind, placebo-controlled, phase III study that evaluated the efficacy and safety of tafasitamab in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma who have received ≥1 prior lines of therapy.¹ The trial was powered to assess progression-free survival in patients with follicular lymphoma only and the planned primary analysis was presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition by Sehn et al.¹ Here, we summarize the key results as a visual abstract.

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.